NDA/BLA filed

“On September 5, 2025, the week prior to the planned Biologics License Application ("BLA") submission related to KOSTAIVE, the U.S. Food and Drug Administration requested that the Company delay its submission of the BLA filing based on the FDA's expectation of providing additional advice.”